Company intelligence / Profile preview

Nuclear Research and Consultancy Group

Petten, North Holland, Netherlands

Ownership: Private
Employees: ~675
Development stage: Other

Overview

NRG is Europe's most important producer of radionuclides including molybdenum-99, lutetium-177, and iridium-192. The company supplies medical isotopes used in the treatment of over 30,000 cancer patients daily. Lutetium-177 is used for prostate cancer treatment in collaboration with the Netherlands Cancer Institute.

Therapeutic areas: Oncology
Modalities: Radiopharmaceutical
Industry: Contract Manufacturing Organization

Partnerships

Netherlands Cancer Institute (medical isotope applications)

Beyond the preview

Go deeper on Nuclear Research and Consultancy Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuclear Research and Consultancy Group.

Explore the full profile